Christofides N D, Sheehan C P
Cardiff Laboratories, Kodak Clinical Diagnostics Ltd., Amersham, UK.
Clin Chem. 1995 Jan;41(1):17-23.
We describe the development and validation of a one-step nonradioactive immunoassay for free thyroxine (Amerlite-MAB FT4) in serum or plasma, in the dedicated Amerlite enhanced luminescence assay system. A monoclonal antibody to thyroxine (T4), conjugated with horseradish peroxidase (HRP; EC 1.11.1.7), competes for binding with FT4 or with a conjugate of a protein and L-triiodothyronine immobilized onto the surface of the assay microwells. The signal is generated by antibody-HRP bound to the protein-T3 conjugate, with luminol as substrate. The assay design exploits the high sensitivity of luminescence signal detection, permitting minimal sample dilution and T4 sampling by the antibody. It withstands progressive dilution of serum and is unaffected by T4-binding proteins in serum. The disclosure and validation of this FT4 assay follows guidelines recommended by the American Thyroid Association.
我们描述了一种在专用的Amerlite增强化学发光检测系统中用于血清或血浆中游离甲状腺素(Amerlite - MAB FT4)的一步法非放射性免疫测定方法的开发与验证。一种与辣根过氧化物酶(HRP;EC 1.11.1.7)偶联的抗甲状腺素(T4)单克隆抗体,与游离甲状腺素(FT4)或固定在检测微孔表面的蛋白质与L - 三碘甲状腺原氨酸结合物竞争结合。信号由结合在蛋白质 - T3结合物上的抗体 - HRP产生,以鲁米诺为底物。该检测设计利用了化学发光信号检测的高灵敏度,允许最小限度的样品稀释以及抗体对T4的采样。它能耐受血清的逐步稀释,且不受血清中T4结合蛋白的影响。这种FT4检测方法的公开与验证遵循了美国甲状腺协会推荐的指南。